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บทคดัยอ่ 
วตัถปุระสงค:์ เพื่อศกึษาหาความสมัพนัธร์ะหว่างระดบั hemoglobin และเภสชั
จลนศาสตร์ของยา tacrolimus ในผู้ป่วยไทยที่ได้ร ับการปลูกถ่ายไต วิธี
การศึกษา: ทําการศกึษาแบบยอ้นหลงัในผูป้่วยปลูกถ่ายไต จํานวน 71 คน ทีม่า
ตดิตามการรกัษา ณ โรงพยาบาลจุฬาลงกรณ์ กรุงเทพ โดยเกบ็ขอ้มลูระดบัความ
เข้มข้นยาจากเวชระเบียน ในระยะ 1 ถึง 6 เดือนหลงัได้รบัยา tacrolimus 
คาํนวณหาค่าสดัสว่นขนาดยาต่อความเขม้ขน้ของยา tacrolimus ในเลอืดทีเ่วลา
ก่อนให้ยามื้อถดัไป (D/Ctrough) และหาความสมัพนัธ์ระหว่างระดบั hemoglobin 
และ D/Ctrough โดยการวิเคราะห์ความถดถอยเชิงเส้น ผลการศึกษา: จาก
การศกึษาพบว่า ระดบั hemoglobin มคีวามสมัพนัธเ์ชงิลบกบัค่า D/Ctrough (r = -
0.41, P < 0.01) และไดส้มการทํานายค่าสดัสว่นขนาดยาต่อความเขม้ขน้ยาคอื 
D/Ctrough (L/kg) = 26.38 - 1.44 Hemoglobin (g/dl) นอกจากนัน้ค่า D/Ctrough ใน
กลุ่มผูป้่วยทีม่รีะดบั hemoglobin ตํ่ากว่า 12 กรมั/ดล. มคี่าสงูกว่ากลุ่มผูป้่วยทีม่ ี
ระดบั hemoglobin ปกตอิย่างมนียัสาํคญัทางสถติ ิ(11.10  8.73 และ 7.31  4.05 
L/kg ตามลําดบั). สรปุ: ค่าสดัสว่นขนาดยาต่อความเขม้ขน้ของยา tacrolimus ที่
เวลาก่อนใหย้ามคีวามสมัพนัธก์บัระดบั hemoglobin การเปลีย่นแปลงของระดบั 
hemoglobin อาจช่วยในการปรบัขนาดใชย้า tacrolimus ใหม้คีวามปลอดภยัและ
ประสทิธผิลดใีนผูป้ว่ยปลกูถ่ายไต 
คาํสาํคญั: hemoglobin, kidney transplant, pharmacokinetics, tacrolimus 
Abstract 
Objective: To determine the relationship between hemoglobin levels and 
pharmacokinetics of tacrolimus in Thai kidney transplant patients. 
Methods: The clinical data of 71 kidney transplant recipients at King 
Chulalongkorn Memorial Hospital, Bangkok were retrospectively collected 
during 1 to 6 months after initiation of tacrolimus treatment. The ratio of 
dose to trough whole-blood concentrations of tacrolimus (D/Ctrough) was 
calculated. Linear regression was used to determine the relationship 
between hemoglobin levels and D/Ctrough. Results: Hemoglobin levels were 
inversely associated with D/Ctrough (r = -0.41, P < 0.01). The relationship 
could be described as an equation (D/Ctrough (L/kg) = 26.38 - 1.44 
Hemoglobin (g/dl)).  Furthermore, D/Ctrough was significantly higher in the 
patients with low hemoglobin levels (<12 g/dL) than those with normal 
hemoglobin levels (11.10  8.73 vs 7.31  4.05 L/kg, respectively). 
Conclusion: The ratio of dose to trough concentrations of tacrolimus 
significantly correlates with hemoglobin levels. We should consider 
hemoglobin levels of kidney transplant patients whenever modifying their 
tacrolimus dosage.   
Keywords: hemoglobin, kidney transplant, pharmacokinetics, tacrolimus 
 
 
 
Introduction
Tacrolimus is a potent calcineurin-inhibitor immune-
suppressant indicated for prophylaxis of kidney rejection in 
patients receiving allogenic kidney transplant and improves 
graft survival.1-3 The pharmacokinetic parameters of 
tacrolimus are quite variable among individuals.4,5 With a 
narrow therapeutic index, therapeutic use of tacrolimus is 
quite complicated. Adequate immunosuppression is crucial to 
prevent acute rejection, while overimmunosuppression can 
lead to nephrotoxicity, infections and increased risk of other 
complications. There is a poor correlation between blood 
concentrations of tacrolimus and drug dosage.5,6 Therapeutic 
drug monitoring is necessary to ensure appropriate 
immunosuppression and to avoid adverse drug reactions.  
Trough whole blood concentration of tacrolimus is a good 
indicator of the total body exposure of tacrolimus. A strong 
correlation existed between the trough concentrations (C0) of 
tacrolimus in whole blood and area under the concentration-
time curve from time 0 to 12 hours (AUC0-12).7 It has been 
shown that trough whole blood concentrations of tacrolimus 
are significantly related to clinical endpoints, i.e. there was a 
significant correlation between increased trough 
concentrations and decreased rejection episodes.8,9 Several 
studies have been reported a correlation between high 
trough whole blood concentrations of tacrolimus and toxicity, 
particularly nephrotoxicity and neurotoxicity.10-14 In clinical 
practice, target trough concentration is determined according 
to individual patient’s risks of rejection and toxicity, 
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tacrolimus dosage is then adjusted to achieve the 
predetermined target concentration.3,15 
In systemic circulation, tacrolimus is primarily distributed 
to erythrocytes.16 Since tacrolimus is a low hepatic extraction 
ratio drug, its hepatic clearance might be influenced by 
changes in erythrocyte binding, resulting in interindividual 
variations of the tacrolimus dosage to achieve target 
concentration.17 Anemia is one of the common clinical 
conditions found in pre-transplant chronic kidney disease 
and post-kidney transplant patients. Hematocrit or 
hemoglobin level is one of the plausible factors affecting 
interindividual variability of tacrolimus pharmacokinetics. The 
inverse relationship between tacrolimus clearance and 
hematocrit has been reported in some studies in kidney 18-20 
and liver 21, 22 transplant recipients. However, other studies 
observed no significant relationship.23,24 The coefficient of 
variation for same-sample hematocrit is greater than that for 
hemoglobin.25 A change in plasma volume affects hematocrit 
level. Severity of anemia is, therefore, assessed best by 
measuring hemoglobin levels rather than hematocrit levels.  
The purpose of this study was to determine whether 
hemoglobin levels affect the ratio of dose to trough whole-
blood concentrations of tacrolimus (D/Ctrough) of tacrolimus in 
Thai kidney transplant patients. 
 
Materials and Methods 
Patients 
A retrospective analysis of data from 71 adult kidney 
transplant patients who came to follow up at King 
Chulalongkorn Memorial Hospital, Bangkok, Thailand during 
January 2009 to September 2011 was performed. Drug 
concentration data and relevant patient information were 
obtained at steady-state (between 1 - 6 months after 
initiation of tacrolimus) from clinical patient medication 
profiles and therapeutic drug monitoring records. A same 
daily dose of tacrolimus must be continued for at least 8 
days before blood sample data were gathered to ensure that 
tacrolimus blood concentrations were under steady-state 
conditions. Patients with history of cirrhosis, patients with 
hepatocellular carcinoma or patients with the last hepatic 
enzyme greater than 3 times of upper normal limit value 
(AST > 120 U/L and ALT > 150 U/L) were excluded from this 
study. Additional exclusion criteria were patients who were 
receiving co-medications that could interfere the 
pharmacokinetics of tacrolimus (excepted prednisolone) i.e., 
rifampicin, amobarbital, phenobarbital, phenytoin, diltiazem, 
nifedipine, clarithromycin, erythromycin, telithromycin, 
clotrimazole, fluconazole, itraconazole, ketoconazole, 
voriconazole, protease inhibitors or sirolimus.  
The study was obtained the clinical clearance by the 
Institutional Review Board of Faculty of Medicine, 
Chulalongkorn University, Bangkok, Thailand (COA No. 
186/2011 IRB No. 042/54, Date of approval: April 7, 2011).  
 
Drug Administration 
Initially, all patients received oral tacrolimus (Prograf®) 
therapy as part of their triple immunosuppressive regimens 
comprising tacrolimus and prednisolone with either 
mycophenolate or azathioprine. During 1 to 6 months after 
initiation of tacrolimus therapy, mycophenolate or 
prednisolone were withdrawn in 5 patients because of the 
adverse events or coexisting illness. The recommended 
initial dose of tacrolimus was 0.05 mg/kg twice daily. 
Subsequent dose were adjusted on the basis of clinical 
evidence of efficacy and toxicity and to maintain tacrolimus 
trough blood concentrations between 4 and 10 ng/ml during 
the first year following transplantation. All patients were 
educated by a pharmacist in kidney transplant team to take 
tacrolimus at 8 am and 8 pm and avoid using any drugs that 
may interact with tacrolimus.  
 
Analytical Methods 
Whole blood tacrolimus concentrations were determined 
by chemiluminescent microparticle immunoassay (CMIA) 
method with the ARCHITECT system® I1000SR analyzer. 
According to manufacturer’s information, a limit of 
quantification of assay was 0.8 ng/ml. The linear range of 
the assay was up to 30 ng/ml. Blood concentrations higher 
than 30 ng/ml were diluted according to the manufacturer’s 
protocol. The intra and interassay coefficient of variation for 
tacrolimus concentrations at 5, 11, and 22 ng/ml were less 
than 10%. The mean recovery with tacrolimus concentrations 
at 6.9, 9.3, 15.2, and 18.8 ng/ml was 102% (98 to107%). 
 
Statistical Analysis  
The correlation between the ratio of dose to trough 
concentrations of tacrolimus and hemoglobin levels was 
analyzed using simple linear regression. The means of data 
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were compared by student’s t-tests. The differences at p-
value less than 0.05 were considered statistical significant.  
 
Results 
Drug concentration data and relevant patient information 
were gathered from 30 living and 41 cadaveric kidney 
transplant recipients. Their mean age was 45 years and their 
mean body weight was 59 kg. Forty-four (62%) patients were 
male. The characteristics of the patients are shown in Table 
1.  
All patients were administered oral tacrolimus every 12 
hours. Data of tacrolimus blood concentration were collected 
only if the patients did not receive any operation, dialysis nor 
plasma exchange. The same daily doses of tacrolimus were 
continued for 37.72  24.72 days (ranging from 8 to 123 
days). The medication records were checked to ensure that 
the patients did not receive any medications that can 
interfere tacrolimus pharmacokinetics except prednisolone.  
 
Table 1 Characteristics of patients and immunosuppressive 
treat-ments.  
Characteristics Mean ± SD (Range) 
Age (years) 44.88 ± 10.09 (18.40-65.56) 
Body weight (kg) 59.05 ± 11.88 (37.00-91.20) 
Body mass index (kg/m2) 21.99 ± 3.53 (16.01-31.63) 
Number of renal transplant, n (%)  
First renal transplant 66 (93.0) 
Second real transplant 5 (7.0) 
Type of donor, n (%)  
Deceased donors 41 (57.7) 
Living donors 30 (42.2) 
Indication of tacrolimus therapy, n (%)  
Primary therapy 44 (62.0) 
Rescue therapy 26 (36.6) 
Intolerance therapy 1 (1.4) 
Days postoperation (days) 98.00 (33.00-6,140.00)* 
Duration of tacrolimus therapy (days) 91.72 ± 30.14 (34.00-194.00) 
Biological and clinical data  
Hemoglobin (g/dl) 11.93 ± 2.01 (7.60-16.70) 
Hematocrit (%) 37.30 ± 6.63 (22.90-55.70) 
Albumin (n = 49 patients) (g/dl)  4.16 ± 0.31 (3.20-4.70) 
Serum creatinine (mg/dl) 1.63 ± 0.69 (0.69-4.43) 
Thai eGFR (mg/min/1.73 m2) 61.73 ± 18.47 (19.75-114.75) 
Associated  treatments   
Mycophenolate mofetil (n = 46 patients) 
(mg/day) 
1,239.13 ± 311.61 (750.00-2,000.00)  
Mycophenolate sodium (n = 17 patients) 
(mg/day) 
974.12 ± 169.08 (720.00-1,080.00) 
Azathioprine (n = 4 patients) (mg/day) 75.00 ± 28.87 (50.00-100.00) 
Prednisolone (n = 69 patients) (mg/day) 10.42 ± 5.45 (1.25-20.00) 
* Days postoperation value are median (range).  
Thai eGFR = 375.5 x Scr (-0.848) x Age (-0.364) x 0.712 (if female), where Thai eGFR is Thai estimated 
glomerular filtration rate (mg/min/1.73 m2), Scr is serum creatinine (mg/dl) and Age is age of 
patient (years). 29 
 
 
 
Table 2 Characteristics of tacrolimus treatment. 
Tacrolimus treatment Mean ± SD (Range) 
Maintenance dose of tacrolimus (mg/kg) 0.06 ± 0.37 (0.01-0.22) 
Trough blood concentration (ng/ml) 7.87 ± 3.84 (1.90-19.45) 
BW-adjusted D/Ctrough (L/kg)  9.23 ± 7.05 (1.38-38.96) 
Patients with low hemoglobin level (Hb < 12 g/dl) (n = 36) 11.10 ± 8.73** 
Patients with normal hemoglobin level (Hb ≥ 12 /dl) (n = 35) 7.31 ± 4.05 
D is the oral dose of tacrolimus (mg/kg), Ctrough is the trough blood concentrations of tacrolimus 
(ng/ml) and BW is the body weight. 
** P-value = 0.02, comparing with patients whose hemoglobin levels ≥ 12 g/dl 
 
The mean dose of tacrolimus was 0.06  0.37 mg/kg and the 
corresponding mean trough concentration was 7.87  3.84 
ng/ml as presented in Table 2. All blood concentrations were 
obtained near (less than 15 minutes before or after) to the 
trough (12 hours after previous dose).  
Figures 1 and 2 show plots of observed trough blood 
concentrations against maintenance doses of tacrolimus and 
the relationship between hemoglobin levels and D/Ctrough of 
tacrolimus, respectively. Statistical evaluation of the data 
indicated a negative significant correlations between D/Ctrough 
of tacrolimus and hemoglobin levels (r = -0.41, P < 0.01). 
The relationship describing D/Ctrough was body weight-
adjusted D/Ctrough (L/kg) = 26.378 – 1.437 Hgb while Hgb is 
hemoglobin levels in g/dl.  
The ratio of dose to trough concentrations of tacrolimus 
in the patients with low hemoglobin levels (<12 g/dl) and 
those with normal hemoglobin levels (>12 g/dl) were 11.10  
8.73 and 7.31  4.05 L/kg, respectively with P = 0.02 as 
shown in Table 2.  
 
 
 
Figure 1 Scatter plot of observed trough blood concentrations at 
steady-state (ng/ml) and maintenances dose of 
tacrolimus (mg/kg) in 71 clinical kidney transplant 
patients. 
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Figure 2 Relationship between hemoglobin levels (g/dl) and BW-
adjusted D/Ctrough of tacrolimus (L/kg) (r = -0.41, P < 
0.01). 
 
Discussions and Conclusions 
The relationship between hemoglobin and tacrolimus 
clearance has not been previously reported. Effect of 
hematocrit on pharmacokinetics of tacrolimus has been 
demonstrated in adult kidney transplant patients.18, 19 There 
was a negative correlation between hematocrit levels and 
the ratio of dose to trough concentrations of tacrolimus (r =  
-0.84, P = 0.02).18 An inverse association between 
hematocrit levels and the drug apparent clearance were also 
found (r2 = 0.24).19 The relationship between hematocrit and 
clearance was as well reported in pediatric patients. The 
pediatric kidney transplant recipients with low-hematocrit 
level (< 33%) had higher tacrolimus clearance than those 
with high-hematocrit levels (≥ 33%) with statistical 
significance (p = 0.007).20  
There are some concerns regarding the use of 
hematocrit as a monitoring parameter of anemia.25 First, 
severity of anemia is assessed best by measuring 
hemoglobin levels rather than hematocrit levels. A low 
hematocrit reflects a low number of circulating red blood 
cells and is an indicator of a decrease in the oxygen-carrying 
capacity or of overhydration. A high hematocrit may reflect 
an absolute increase in the number of erythrocytes, or a 
decrease in plasma volume. Second, the coefficient of 
variation for same-sample hematocrit is greater than that for 
hemoglobin. Within-run and between-run coefficients of 
variation in automated analyzer measurement of hemoglobin 
are one half and one third those for hematocrit, respectively. 
The variability in this hematocrit measurement is greater 
because blood-sample storage conditions have no effect on 
hemoglobin measurement but hematocrit increases with 
storage temperature and duration. Third, the hematocrit is 
typically measured from a blood sample by an automated 
machine.  Most of the machines, instead of directly measure, 
calculate hematocrit level based on the determination of the 
amount of hemoglobin and the average volume of the red 
blood cells. Moreover, hyperglycemia is related to an 
increase in MCV and elevates the hematocrit result.25 
During 1-6 months (early stage) after transplantation, 
risks of rejection and infection are very high. Optimization of 
immunosuppressive therapy is, therefore, crucial. This study 
was conducted to determine a correlation between 
hemoglobin levels and ratio of dose to trough whole-blood 
concentrations of tacrolimus during the early stage of post-
transplantation. The routine therapeutic drug monitoring data 
during 1-6 months after initiation of tacrolimus treatment from 
71 Thai kidney transplant patients were collected, reviewed, 
and analyzed.  
We observed the inverse relationship between 
hemoglobin levels and D/Ctrough of tacrolimus (r = -0.41, P < 
0.01). The association could be described as D/Ctrough (L/kg) 
= 26.378 – 1.437 Hgb while Hgb is hemoglobin levels in g/dl 
(r2 = 0.17). It was also found that the ratio of D/Ctrough of 
tacrolimus was significantly higher in the patients with 
hemoglobin <12 g/ml than those with normal hemoglobin > 
12 g/ml (P = 0.02).  
The ratio of dose to trough whole-blood concentrations of 
tacrolimus was considered to be proportional to the total 
body clearance and was referred to as relative clearance at 
steady state in several studies.18,21,26 One possible 
explanation for the higher ratio of dose to trough 
concentrations of tacrolimus among patients with decreased 
hemoglobin could be changed in unbound fraction. Since 
tacrolimus is extensively bound to erythrocytes, resulting in 
the distribution ratio of 35 (range 12 to 67) for tacrolimus 
whole blood concentrations to plasma concentrations.16 And 
tacrolimus is a low hepatic clearance drug with the extraction 
ratio about 3% of hepatic blood flow.17,18 Tacrolimus 
clearance is influenced by changes in its unbound fraction 
and hepatic enzyme activity (intrinsic clearance).17,27 Low 
hemoglobin level probably results in a reduced fraction of 
tacrolimus bound to erythrocytes and an increased plasma 
unbound fraction, which was more metabolized by the liver.  
The drug’s clearance is an important factor determining 
the oral maintenance dosage which produce a desired 
average plasma concentration at steady state.28 Knowing the 
influence of hemoglobin on D/Ctrough may be used as a guide 
in the adjustment of tacrolimus dose. Patients with lower 
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levels of hemoglobin would need higher daily tacrolimus 
dosage to achieve the target level for prophylaxis of renal 
allograft rejection. When hemoglobin levels decreased, the 
ratio of dose to trough concentrations was, thereby, 
increased, higher tacrolimus doses might be required to 
maintain the target blood concentrations. In patients whose 
hemoglobin level is changing, their tacrolimus levels should 
be monitored and dosage adjustments may be required to 
maintain steady-state blood concentrations within their target 
ranges. 
A plot of observed steady-state trough blood concen-
trations against maintenance doses of tacrolimus (Figure 1) 
shows non-linear relationship between doses and tacrolimus 
steady-state trough concentrations (r = 0.10, P = 0.40). This 
may partially explained that tacrolimus exhibits highly 
interpatient variability in its pharmacokinetics. Therapeutic 
drug monitoring is necessary for optimal prevention of renal 
transplant rejection.  
It should be emphasized the clearance we discussed 
here are the clearance of total drug (both bound and 
unbound forms); however, the unbound clearance of the low 
hepatic extraction drug is not affected by the change of 
unbound fraction, thus, careful interpretation of this results 
would be prudent. The total concentration of tacrolimus may 
be observed to be lower; however, with the lower concen-
tration of hemoglobin resulting in the higher unbound 
fraction, thus, the unbound concentration may not be as low 
as we estimate from the total concentration of tacrolimus. 
D/Ctrough of tacrolimus, though is significantly correlated 
with hemoglobin levels, might be influenced by different 
factors. In order to describe other factors, such as various 
demographic, hematological, biochemical parameters and 
genetic polymorphisms of the drug metabolizing enzymes 
and drug transporters that affect the variability in tacrolimus 
pharmacokinetics in Thai kidney transplant patients, the 
population pharmacokinetics study of tacrolimus including 
these factors is needed in future studies.   
In conclusion, we demonstrated the relationship between 
hemoglobin levels and the ratio of dose to trough 
concentrations of tacrolimus by using clinical data from Thai 
kidney transplant patients. To modify tacrolimus dosage in 
renal transplant patients, we should consider hemoglobin 
levels as one factor influencing drug levels. 
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